Skip to content
value.today

CervoMed Inc.

CRVO
$26 Mmarket cap on Oct 30, 2026
Compare
World rank
#23,458
Revenue
$4 M
For year ending December-2025
Net income
$-27 M
-672.6% margin
SEC filing
Employees
15
As of December 31, 2025
SEC filing

CervoMed Inc. in brief

CervoMed Inc. is a listed company in the Biotechnology industry, based in Boston, Massachusetts, USA. Its market value was $26 M on 30 October 2026, which makes it the 23,458th largest listed company in the world and the 4,071st largest in the USA on this site. In the year to December 2025 it had sales of $4 M and a net loss of $27 M. It employs about 15 people. Its shares trade under the symbol CRVO (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About CervoMed Inc.

We are a clinical-stage biotechnology company developing treatments for age-related brain disorders. Our lead drug candidate, neflamapimod, is an investigational, orally administered small-molecule drug that readily crosses the blood brain barrier and selectively inhibits the enzyme p38α, a key driver of neuroinflammation and synaptic dysfunction. By targeting the critical disease processes underlying degenerative disorders of the brain, neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression. Neflamapimod is currently in clinical development for the treatment of DLB, our lead indication, as well as nfvPPA, RAS, and ALS.

From the company's annual report filed with the US SEC: read the report

CervoMed Inc. timeline

7 events, 1998–2024
  1. 1998
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2008
  4. ✎
    Renamed Feris International, Inc.
    Formerly Titan Motorcycle Co Of America Inc.
  5. ✎
    Renamed Stratus Media Group, Inc
    Formerly Feris International, Inc..
  6. 2014
  7. ✎
    Renamed RestorGenex Corp
    Formerly Stratus Media Group, Inc.
  8. 2016
  9. ✎
    Renamed Diffusion Pharmaceuticals Inc.
    Formerly RestorGenex Corp.
  10. 2023
  11. ✎
    Renamed CervoMed Inc.
    Formerly Diffusion Pharmaceuticals Inc..
  12. 2024
  13. 💰
    Record revenue of $10 million
    FY2024, the highest of the 3 years on record.

Events of CervoMed Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$9 M$19 M$28 M$37 M

World rank over time

▼ down 803 places since 2026
2026-10-14: #22669#22,66920262026-10-30: #23472#23,4722026

Rank in USA: #3,981 (Oct 2026) · #4,074 (Oct 2026)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
6.6×
Price / book
1.5×
Free cash flow yield
-48.3%
Net margin
-672.6%
Operating margin
-705.5%
Return on equity
-148.0%
Liabilities / assets
20.4%
Revenue growth
-58.8%
R&D / revenue
544.1%
Revenue per employee
$267 K
Profit per employee
$-1.8 M

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue —, net income $-18M—FY18Fiscal year ending Dec 2019: revenue —, net income $-12M—FY19Fiscal year ending Dec 2020: revenue —, net income $-14M—FY20Fiscal year ending Dec 2021: revenue —, net income $-24M—FY21Fiscal year ending Dec 2022: revenue —, net income $-6M—FY22Fiscal year ending Dec 2023: revenue $7M, net income $-2M$7MFY23Fiscal year ending Dec 2024: revenue $10M, net income $-16M$10MFY24Fiscal year ending Dec 2025: revenue $4M, net income $-27M$4MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$4M-58.8%$-28M$-27M-672.6%
Dec 2024$10M+36.4%$-18M$-16M-167.2%
Dec 2023$7M—$-8M$-2M-30.4%
Dec 2022——$-3M$-6M—
Dec 2021——$-25M$-24M—
Dec 2020——$-16M$-14M—
Dec 2019——$-12M$-12M—
Dec 2018——$-19M$-18M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-23M————
Dec 2024$-17M————
Dec 2023$-7M————
Dec 2022$-3M————
Dec 2021$-15M————
Dec 2020$-14M————
Dec 2019$-10M————
Dec 2018$-11M————

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue $2M, net income $-7M$2MDec ’24Three months to Mar 2025: revenue $2M, net income $-5M$2MMar ’25Three months to Jun 2025: revenue $2M, net income $-6M$2MJun ’25Three months to Sep 2025: revenue $0M, net income $-8M$0MSep ’25Three months to Dec 2025 (from the annual report): revenue $0M, net income $-8M$0MDec ’25Three months to Mar 2026: revenue —, net income $-8M—Mar ’26Three months to Jun 2026: revenue —, net income $-7M—Jun ’26Three months to Sep 2026: revenue —, net income $-6M—Sep ’26

Latest quarter to Sep 2026: revenue —, net income $-6M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of CervoMed Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$4 M
Operating income
$-28 M
Net income
$-27 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$23 M
Total liabilities
$5 M
Total equity
$18 M

As of December-2025

Top 36 institutional investors in CervoMed Inc.#

As of Sep 30, 2026
36 institutions held 1.3 M shares (about 8.8% of the shares outstanding) on Sep 30, 2026. The ten largest hold 7.6%. Source: SEC Form 13F filings, filed through Nov 18, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in CervoMed Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Vanguard Capital Management LLC316,2020 (0.00%)2.09%$1 MNov 13, 2026
2Woodline Partners LP238,853-450,134 (-65.33%)1.58%$1 MNov 16, 2026
3Sabby Management, LLC199,678-49,202 (-19.77%)1.32%$1 MNov 13, 2026
4Geode Capital Management, LLC92,007+25,084 (+37.48%)0.61%$0 MNov 6, 2026
5BlackRock, Inc.79,663+25,818 (+47.95%)0.53%$0 MNov 13, 2026
6Vanguard Fiduciary Trust Co61,516+25,365 (+70.16%)0.41%$0 MNov 13, 2026
7Byrne Asset Management LLC50,050-1,200 (-2.34%)0.33%$0 MOct 6, 2026
8Citigroup Inc39,334+38,670 (+5823.80%)0.26%$0 MNov 4, 2026
9Citizens Financial Group Inc/ri37,4770 (0.00%)0.25%$0 MOct 23, 2026
10Gsa Capital Partners LLP29,992New0.20%$0 MNov 16, 2026
11Savvy Advisors, Inc.25,9220 (0.00%)0.17%$0 MNov 12, 2026
12Thompson Davis & Co., Inc.25,900-3,850 (-12.94%)0.17%$0 MNov 5, 2026
13State Street Corp20,5270 (0.00%)0.14%$0 MNov 12, 2026
14Summit Financial, LLC18,1400 (0.00%)0.12%$0 MNov 12, 2026
15Northern Trust Corp13,3180 (0.00%)0.09%$0 MNov 16, 2026
16Cetera Investment Advisers12,073-7,549 (-38.47%)0.08%$0 MNov 13, 2026
17Caprock Group, LLC11,585New0.08%$0 MNov 17, 2026
18NFSG Corp11,500+8,500 (+283.33%)0.08%$0 MOct 15, 2026
19HighTower Advisors, LLC11,244-675 (-5.66%)0.07%$0 MNov 10, 2026
20Russell Investments Group, Ltd.8,187-7,176 (-46.71%)0.05%$0 MNov 6, 2026
21FMR LLC5,272-5,266 (-49.97%)0.03%$0 MNov 10, 2026
22Vanguard Global Advisers, LLC2,5970 (0.00%)0.02%$0 MNov 13, 2026
23UBS Group AG2,559+1,567 (+157.96%)0.02%$0 MNov 10, 2026
24Morgan Stanley2,550-10,149 (-79.92%)0.02%$0 MNov 13, 2026
25Federation des caisses Desjardins du Quebec1,7000 (0.00%)0.01%$0 MNov 16, 2026
Show all 36: investors 26 to 36
Institutional investors 26 to 36 in CervoMed Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Osaic Holdings, Inc.1,517+1,487 (+4956.67%)0.01%$0 MNov 12, 2026
27Royal Bank Of Canada1,353+1,052 (+349.50%)0.01%$0 MNov 16, 2026
28Tower Research Capital LLC (TRC)1,318-855 (-39.35%)0.01%$0 MNov 16, 2026
29Hoey Investments, Inc1,0800 (0.00%)0.01%$0 MOct 29, 2026
30Nuveen, LLC733New0.00%$0 MNov 10, 2026
31Nisa Investment Advisors, LLC145-106 (-42.23%)0.00%$0 MOct 20, 2026
32SBI Securities Co., Ltd.145-110 (-43.14%)0.00%$0 MOct 22, 2026
33BNP Paribas Financial Markets40-51 (-56.04%)0.00%$0 MNov 12, 2026
34Robinhood Markets, Inc.19—0.00%$0 MNov 18, 2026
35Arax Advisory Partners5-12 (-70.59%)0.00%$0 MNov 12, 2026
36Danske Bank A/s10 (0.00%)0.00%$0 MNov 9, 2026

Mutual funds holding CervoMed Inc.#

9 funds hold shares worth $1 M (about 2.7% of the company). Since their previous reports 4 added shares and 1 sold, buying $0 M net.
Mutual funds holding CervoMed Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.250,174$1 M1.7%<0.01%no changeJun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.66,028$0 M0.44%<0.01%no changeJun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC37,241$0 M0.25%<0.01%+14%May 31, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors19,545$0 M0.13%<0.01%+12%Jun 30, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC9,020$0 M0.06%<0.01%no changeMay 31, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC8,992$0 M0.06%<0.01%+16%May 31, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC7,411$0 M0.05%<0.01%+51%May 31, 2026
🇺🇸 Avantis U.S. Small Cap Equity ETFAmerican Century ETF Trust3,281$0 M0.02%<0.01%no changeMay 31, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC1,068$0 M<0.01%<0.01%no changeJun 30, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 9 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at CervoMed Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$3.0 M
1 purchase, 1 insider
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$3.0 M
open market only
Insiders on file
17
since
$3.0 M$0Feb 2024: bought $0 (0 trades), sold $0 (1 trades)Feb 24Aug 2024: bought $18 K (1 trades), sold $0 (0 trades)AugMay 2025: bought $36 K (1 trades), sold $0 (0 trades)MayNov 2025: bought $455 K (18 trades), sold $0 (0 trades)NovJun 2026: bought $3.0 M (1 trades), sold $0 (0 trades)Jun
Bought (open market)Sold (open market)Hover a month for the totals
CervoMed Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Joshua S. BogerDirector, 10% ownerBuyindirect+955,414$3.140$3.0 M1.80 MForm 4
filed Matthew WintonChief Commercial and BusinessBuy+1,500$7.950$12 K15,000Form 4
filed William Robert ElderCFO, GC & SecretaryBuy+2,500$8.320$21 K12,500Form 4
filed Matthew WintonChief Commercial and BusinessBuy+3,500$8.430$30 K13,500Form 4
filed William Robert ElderCFO, GC & SecretaryBuy+1,000$8.450$8 K10,000Form 4
filed Sylvie GregoireDirector, 10% ownerBuy+10,793$8.460—1.48 MForm 4
filed John J. AlamCEO & President, Director, 10% ownerBuy+10,807$8.460$91 K1.48 MForm 4
filed Sylvie GregoireDirector, 10% ownerBuyindirect+10,807$8.460—12,500Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: CervoMed Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
1.2 M
13.1% of shares · 4.65 days to cover
Shares sold short, last 24 reportsAll stocks →

Stock splits: 1-for-100 reverse split

Trading halts

  • 2026-06-18 17:13 UTC, code LUDP, resumed 17:18 UTC
  • 2026-06-18 16:56 UTC, code LUDP, resumed 17:06 UTC
  • 2026-06-18 16:45 UTC, code LUDP, resumed 16:55 UTC
  • 2026-06-18 16:35 UTC, code LUDP, resumed 16:45 UTC
  • 2026-06-18 16:07 UTC, code LUDP, resumed 16:12 UTC

Fails to deliver

  • : 2,891 shares at $1.75
  • : 24,572 shares at $2.21
  • : 285 shares at $2.24
  • : 613 shares at $2.31
  • : 1,487 shares at $2.24

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

CervoMed Inc. scorecard#

Passes 3 of the 14 checks that could be worked out: strongest in valuation (2 of 5), weakest in profitability (0 of 4). Fiscal year 2025; market cap of Oct 30, 2026.

  • Valuation2 of 5
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✓Price to book below its peers' median1.4×Price to book 1.4× against Biotechnology's median of 2.9×.
    • ✓Price to sales below its peers' median6.6×Price to sales 6.6× against Biotechnology's median of 8.7×.
    • ✗Free cash flow yield above 5%-48.3%Free cash flow is -48.3% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth0 of 2
    • ✗Revenue grew in the newest year-58.8%Revenue down 58.8% in fiscal 2025.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • –Earnings per share grew in the newest yearEarnings per share of two years are not on file.
    • ✗Net income higher than five years earlier-$27 M-$27 M in fiscal 2025 against -$14 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 4
    • ✗Profitable in the newest year-$27 MNet income -$27 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • ✗Operating margin above its peers' median-705.5%-705.5% against Biotechnology's median of -60.5% (243 companies).
    • ✗Return on equity above 15%-93.9%-93.9% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 3
    • ✓Short-term assets cover short-term liabilities4.9×Current ratio 4.91 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • ✗Altman Z-score outside the distress zone-5.52Z-score -5.52 (distress zone) for fiscal 2025.
  • Shareholder returnsnot known
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • –Share count up no more than 2% in a yearShare counts of two years are not on file.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2025#

Worked out from CervoMed Inc.'s statements, beside the median of Biotechnology.

CervoMed Inc.: main financial ratios in 2025
Ratio2025Median of peers
Operating margin-705.5%-60.5%
Net margin-672.6%-68.9%
Return on equity-93.9%-61.0%
Revenue growth-58.8%15.8%

1of 7on the Piotroski tests of financial strength

  • Revenue fell 58.8% against the year before.
  • Net loss of $27 million, the 16th loss-making year in a row.

CervoMed Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

CervoMed Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016
Income statement
Revenue4.09.77.10——————
Research and development22198.41.3r8.59.46.65.85.17.3
General and administrative109.26.52.1r7.46.44.86.26.211
Operating expenses3228153.5——————
Operating income−28−18−7.8−3.5r−25−16−12−19−11−18
Interest and finance income1.31.90.20.1——————
Interest expense and finance costs——00.0———0.00.10.0r
Other non-operating income (expense)1.31.95.6−2.3——————
Income before tax———−16−25−16−11−19−2.4−18
Income tax0——0−0.4−1.70.3−0.4−1.1−0.4
Net income attributable to shareholders−27−16−2.2−5.8r−24−14−12−18−1.4−18
Earnings per share, basic-2.98-2.02-0.82-11.20r-12.38r-0.30-1.76-8.21-3.16r-1.76
Earnings per share, diluted————————-29.11r-1.76
Shares, weighted average (basic)9.08.12.70.5———3.20.8r10
Shares, weighted average (diluted)———————3.20.8r10
Balance sheet
Cash and cash equivalents8.29.07.84.1r3719148.08.91.6
Short-term investments13300120—————
Other current assets0.00.20.10.1——————
Current assets234310.04.2r3819158.99.71.6
Property, plant and equipment————00.10.30.40.50.1
Right-of-use (leased) assets————00.10.2———
Goodwill———————06.96.9
Other intangible assets—————————8.6
Total assets234310.04.2r382824182617
Accounts payable1.51.50.70.1r0.90.51.30.20.51.7
Current liabilities4.73.9——2.92.41.70.82.74.4
Lease liabilities (non-current)————00.00.1———
Total liabilities4.73.92.613r2.92.94.02.64.98.3
Retained earnings−98−71−54−52r−130−106−92−80−62−60
Shareholders' equity18397.4−33r35252016219.2
Total equity——7.4−33r−28r252016219.2
Total liabilities and equity234310.04.2r382824182617
Shares outstanding9.38.75.70.5r2.0r64333.41.0r10
Cash-flow statement
Depreciation and amortization———00.10.1————
Share-based compensation1.41.40.40.3r0.90.70.51.21.21.4
Cash from operating activities−23−17−7.4−2.6r−15−14−9.9−11−12−11
Capital expenditure————————−0.4−0.0
Cash from investing activities18−290−120.00——−0.48.5
Shares issued—460.803111—11——
Cash from financing activities4.646110r3318169.9201.8
Change in cash−0.81.23.7−2.6r194.3r6.2−0.97.3−0.4
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Executive pay at CervoMed Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$1.0 M
Other top executives, average
$669 K
the CEO earned 1.6× this
$100 invested is now
$104
CervoMed Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025Chief executive$1.0 M$1.5 M$669 K$104
2024Chief executive$1.0 M$953 K$732 K$31
2023Chief executive$1.5 M$1.4 M$467 K$101

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at CervoMed Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Directors and officers 1 · Material agreement 2 · Unregistered share sale 2 · Shareholder vote 1 · Results announced 6

CervoMed Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Results announced8-K
Material agreementUnregistered share sale8-K
Material agreementUnregistered share sale8-K
Shareholder vote8-K
Results announced8-K
Results announced8-K
Results announced8-K
Directors and officers8-K
Results announced8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 9, 2026

Acquisitions and funding#

2 private funding rounds before listing

Private share sales · funding history

Private share sales of CervoMed Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Mar 2017$16 MPrivate placement after listing$10 to $50 million145equity, optionsSEC
Jan 2016$86 MPrivate placement after listing$50 to $250 million181equitySEC
Apr 2014$25 MPrivate placement after listing$10 to $50 million146equitySEC
May 2011$9 MNo. 2$2 to $10 million8equity, optionsSEC
Apr 2011$3 MNo. 1$2 to $10 million73equity, optionsSEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

Layoffs at CervoMed Inc.#

From US state WARN notices and SEC 8-K restructuring filings, newest first.

People, last 12 months
0
0 notices and filings
People, all years
0
2023–2023
Latest
—
2023-02-16
CervoMed Inc.: people laid off by year and month
YearJanFebMarAprMayJunJulAugSepOctNovDecTotal
2023············—
CervoMed Inc.: latest layoffs
AnnouncedPeopleKindWhereSource
Not statedRestructuring planSEC 8-KCompany-wide planFiling

Source: State WARN notices and SEC 8-K item 2.05

How CervoMed Inc. compares in Biotechnology

  • Market cap$26 M · higher than 20% of 726
  • Revenue$4 M · higher than 34% of 647
  • Net margin-672.6% · higher than 6% of 408
  • Revenue growth-58.8% · higher than 15% of 438
  • Price / sales6.6× · lower than 55% of 339
  • Price / book1.4× · lower than 68% of 534
  • FCF yield-48.3% · higher than 25% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
CervoMed Inc.🇺🇸$26 M—-672.6%-58.8%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 30, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As of December 31, 2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at CervoMed Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show CervoMed Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about CervoMed Inc.? Suggest a correction